JP6027607B2 - プテロスチルベンの抗不安効果 - Google Patents

プテロスチルベンの抗不安効果 Download PDF

Info

Publication number
JP6027607B2
JP6027607B2 JP2014510467A JP2014510467A JP6027607B2 JP 6027607 B2 JP6027607 B2 JP 6027607B2 JP 2014510467 A JP2014510467 A JP 2014510467A JP 2014510467 A JP2014510467 A JP 2014510467A JP 6027607 B2 JP6027607 B2 JP 6027607B2
Authority
JP
Japan
Prior art keywords
pterostilbene
anxiety
composition
functional food
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014510467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514361A (ja
JP2014514361A5 (cg-RX-API-DMAC7.html
Inventor
アグネス エム リマンド
アグネス エム リマンド
アビール エル−アイフィ
アビール エル−アイフィ
ムド アル ラヒム
ムド アル ラヒム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2014514361A publication Critical patent/JP2014514361A/ja
Publication of JP2014514361A5 publication Critical patent/JP2014514361A5/ja
Application granted granted Critical
Publication of JP6027607B2 publication Critical patent/JP6027607B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014510467A 2011-05-11 2012-05-10 プテロスチルベンの抗不安効果 Expired - Fee Related JP6027607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 2011-05-11
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016202351A Division JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Publications (3)

Publication Number Publication Date
JP2014514361A JP2014514361A (ja) 2014-06-19
JP2014514361A5 JP2014514361A5 (cg-RX-API-DMAC7.html) 2015-05-28
JP6027607B2 true JP6027607B2 (ja) 2016-11-16

Family

ID=47140003

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014510467A Expired - Fee Related JP6027607B2 (ja) 2011-05-11 2012-05-10 プテロスチルベンの抗不安効果
JP2016202351A Withdrawn JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016202351A Withdrawn JP2017014284A (ja) 2011-05-11 2016-10-14 プテロスチルベンの抗不安効果

Country Status (9)

Country Link
US (1) US9439875B2 (cg-RX-API-DMAC7.html)
EP (1) EP2706992B1 (cg-RX-API-DMAC7.html)
JP (2) JP6027607B2 (cg-RX-API-DMAC7.html)
KR (1) KR101929074B1 (cg-RX-API-DMAC7.html)
CN (1) CN103561729B (cg-RX-API-DMAC7.html)
AU (1) AU2012253479B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013028776B1 (cg-RX-API-DMAC7.html)
CA (1) CA2839309C (cg-RX-API-DMAC7.html)
WO (1) WO2012154956A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017014284A (ja) * 2011-05-11 2017-01-19 アメリカ合衆国 プテロスチルベンの抗不安効果

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682032B2 (en) * 2013-03-15 2017-06-20 Glia, Llc Cranial delivery of pharmaceuticals
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
BR112019003579A2 (pt) 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020999A2 (en) * 2004-08-19 2006-02-23 The United States Of America, As Represented By The Secretary Of Agriculture Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
WO2009082459A2 (en) * 2007-12-24 2009-07-02 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Ｊｎｃ株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
WO2010095926A1 (en) * 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
ES2798254T3 (es) * 2009-06-22 2020-12-10 Indus Biotech Private Ltd Proceso para la obtención de pteroestilbeno purificado y métodos de uso del mismo
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017014284A (ja) * 2011-05-11 2017-01-19 アメリカ合衆国 プテロスチルベンの抗不安効果

Also Published As

Publication number Publication date
KR101929074B1 (ko) 2018-12-13
US20160067192A1 (en) 2016-03-10
HK1194302A1 (zh) 2014-10-17
JP2014514361A (ja) 2014-06-19
EP2706992A4 (en) 2014-12-17
JP2017014284A (ja) 2017-01-19
AU2012253479A1 (en) 2013-11-28
WO2012154956A2 (en) 2012-11-15
EP2706992B1 (en) 2019-09-04
WO2012154956A3 (en) 2013-01-24
AU2012253479B2 (en) 2016-12-22
KR20140107112A (ko) 2014-09-04
CA2839309A1 (en) 2012-11-15
BR112013028776B1 (pt) 2022-04-19
BR112013028776A2 (pt) 2017-01-24
CA2839309C (en) 2019-05-07
CN103561729A (zh) 2014-02-05
EP2706992A2 (en) 2014-03-19
US9439875B2 (en) 2016-09-13
CN103561729B (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
JP6027607B2 (ja) プテロスチルベンの抗不安効果
Kamal et al. Beneficial health effects of glucosinolates-derived isothiocyanates on cardiovascular and neurodegenerative diseases
TW202139980A (zh) 以大麻二酚及依維莫司(everolimus)治療結節性硬化症之方法
US10617733B2 (en) Orally consumable cannabinoid composition including lecithin
RU2563991C2 (ru) Синергические комбинации каротиноидов и полифенолов
TW201033182A (en) Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
EP3478276B1 (en) Methods for inhibiting conversion of choline to trimethylamine (tma)
JP2017501975A (ja) 認知症を予防及び／又は治療するための薬剤の調製におけるジンセノサイドＲｇ３の適用、並びに認知症を治療する薬剤
TW202140034A (zh) 化合物及其醫藥用途
Elkholy et al. Cationic liposome-encapsulated carotenoids as a potential treatment for fibromyalgia in an animal model
US10912812B2 (en) Methods for preparing botanical extracts
Lian et al. Cornuside ameliorates cognitive impairments via RAGE/TXNIP/NF-κB signaling in Aβ1-42 induced Alzheimer’s disease mice
Sui et al. Metabolites of procyanidins from Litchi chinensis pericarp with xanthine oxidase inhibitory effect and antioxidant activity
Yin et al. Xiyangshen Sanqi Danshen granules attenuated D-gal-induced C57BL/6J mouse aging through the AMPK/SIRT1 signaling pathway
Du et al. The cannabinoid WIN 55,212-2 reduces delayed neurologic sequelae after carbon monoxide poisoning by promoting microglial M2 polarization through ST2 signaling
US10329315B2 (en) Glycosphingolipids and methods of use thereof
Jia et al. Metformin ameliorates postoperative cognitive dysfunction through regulation of the AMPK/SIRT1 pathway
HK1194302B (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
KR20130046138A (ko) 소회향 추출물을 포함하는 염증성 질환의 예방 또는 치료용 조성물
Chen et al. NMC‐4 Ameliorates Depression‐Like Behavior and Neuroinflammation Caused by Chronic Unpredictable Mild Stress
JP2019521184A (ja) 糖尿病および他の変性慢性複合疾患によって生じる慢性損傷促進性細胞老化を元の状態に戻すおよび予防するための、代謝バイオエネルギー調節因子とニュートラエピジェネティック調節因子の組合せ、従来技術とナノテクノロジーを組み合わせた栄養補助化合物
Yunusova et al. The Influence of Monoammonium Salt of Glycyrrhizinic Acid and Acetylsalicylic Acid on Cardiac and Hematological Processes in Rats with Experimental Myocarditis
WO2022173750A1 (en) Xanthohumol derivatives and methods for making and using
WO2024127401A1 (en) Pulicaria incisa infusion for reducing neuronal cell death and treating age-related neuronal pathologies
JP2025513458A (ja) ヨーグルト中の生体活性分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160914

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161014

R150 Certificate of patent or registration of utility model

Ref document number: 6027607

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees